



16 October 2017

ASX ANNOUNCEMENT

Chairman sells 4.35 million shares

The Chairman of Medical Developments Limited (ASX: MVP), Mr. David Williams has given notice that he sold 4.35 million shares at \$5.40. Mr. Williams said he sold the shares to “make room for two large European Institutional investors”.

Mr. David Williams still remains a substantial shareholder of MVP, having a remaining indirect interest in 13,694,874 shares and as a consequence of this, a ‘Notice of Change of Interests of Substantial Shareholder’ will soon be released.

Enquiries:

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

David Williams
Chairman
Medical Developments International Ltd
0414 383 593

**About Pentrox**

Penthrox is a non-opioid, non-addictive, inhaled analgesic indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used for more than 40 years in Australia and is now sold into 16 countries with circa 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy. Penthrox is also sold in numerous countries internationally including within the UK, Ireland, France and Belgium.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, an analgesic product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.